報價延遲最少15分鐘:2024/12/23 22:26 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.07 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.95/-0.90
|
|
企業價值
284.85M
|
| 資產負債 |
|
每股賬面淨值
0.74
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
488.00K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:26 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). |